Greer Alisha, Hewitt Mark, Khazaneh Parsa T, Ergan Begum, Burry Lisa, Semler Matthew W, Rochwerg Bram, Sharif Sameer
Department of Medicine, Division of Emergency Medicine, McMaster University, Hamilton, ON, Canada.
Department of Medicine, Division of Critical Care, McMaster University, Hamilton, ON, Canada.
Crit Care Med. 2025 Feb 1;53(2):e374-e383. doi: 10.1097/CCM.0000000000006515. Epub 2024 Nov 21.
To compare the safety and efficacy of ketamine and etomidate as induction agents to facilitate emergent endotracheal intubation.
We searched MEDLINE, Embase, Cochrane Clinical Trials Register, and ClinicalTrials.gov from inception to April 3, 2024.
We included randomized controlled trials (RCTs) that compared ketamine to etomidate to facilitate emergent endotracheal intubation in adults.
Reviewers screened abstracts, full texts, and extracted data independently and in duplicate. We pooled data using a random-effects model, assessed risk of bias using the modified Cochrane tool and certainty of evidence using the Grading Recommendations Assessment, Development, and Evaluation approach. We pre-registered the protocol on PROSPERO (CRD42023472450).
We included seven RCTs ( n = 2384 patients). Based on pooled analysis, compared with etomidate, ketamine probably increases hemodynamic instability in the peri-intubation period (relative risk [RR], 1.29; 95% CI, 1.07-1.57; moderate certainty) but probably decreases the need for initiation of continuous infusion vasopressors (RR, 0.75; 95% CI, 0.57-1.00; moderate certainty) and results in less adrenal suppression (RR, 0.54; 95% CI, 0.45-0.66; moderate certainty). Ketamine probably has no effect on successful intubation on the first attempt (RR, 1.01; 95% CI, 0.97-1.05; moderate certainty) or organ dysfunction measured as the maximum Sequential Organ Failure Assessment (SOFA) score during the first 3 days in ICU (mean difference, 0.55 SOFA points lower; 95% CI, 1.12 lower to 0.03 higher; moderate certainty) and may have no effect on mortality (RR, 1.00; 95% CI, 0.83-1.21; low certainty) when compared with etomidate.
Compared with etomidate, ketamine probably results in more hemodynamic instability during the peri-intubation period and appears to have no effect on successful intubation on the first attempt or mortality. However, ketamine results in decreased need for the initiation of vasopressor use and decreases adrenal suppression compared with etomidate.
比较氯胺酮和依托咪酯作为诱导剂在急诊气管插管中的安全性和有效性。
我们检索了MEDLINE、Embase、Cochrane临床试验注册库和ClinicalTrials.gov,检索时间从创建至2024年4月3日。
我们纳入了比较氯胺酮和依托咪酯在成人急诊气管插管中应用的随机对照试验(RCT)。
reviewers独立且重复地筛选摘要、全文并提取数据。我们使用随机效应模型汇总数据,使用改良的Cochrane工具评估偏倚风险,并使用分级推荐评估、发展和评价方法评估证据的确定性。我们在PROSPERO(CRD42023472450)上预先注册了方案。
我们纳入了7项RCT(n = 2384例患者)。基于汇总分析,与依托咪酯相比,氯胺酮可能会增加插管期血流动力学不稳定(相对风险[RR],1.29;95%置信区间[CI],1.07 - 1.57;中等确定性),但可能会减少持续输注血管加压药的需求(RR,0.75;95% CI,0.57 - 1.00;中等确定性),并减少肾上腺抑制(RR,0.54;95% CI,0.45 - 0.66;中等确定性)。氯胺酮可能对首次插管成功无影响(RR,1.01;95% CI,0.97 - 1.05;中等确定性),也不影响在ICU的前3天内以最大序贯器官衰竭评估(SOFA)评分衡量的器官功能障碍(平均差异,SOFA评分低0.55分;95% CI,低1.12分至高0.03分;中等确定性),与依托咪酯相比,可能对死亡率无影响(RR,1.00;95% CI,0.83 - 1.21;低确定性)。
与依托咪酯相比,氯胺酮可能在插管期导致更多血流动力学不稳定,且似乎对首次插管成功或死亡率无影响。然而,与依托咪酯相比,氯胺酮可减少血管加压药的使用需求并减轻肾上腺抑制。